Have a personal or library account? Click to login
Effect of amygdalin on MCF-7, MDA-MB-231 and T-47D breast cancer cells in the in vitro study Cover

Effect of amygdalin on MCF-7, MDA-MB-231 and T-47D breast cancer cells in the in vitro study

Open Access
|Apr 2022

Abstract

Introduction

Amygdalin is a chemical compound found in the seeds of many edible plants. Different studies using cancer cell cultures in vitro indicate its potential anti-cancer activity. Various types of cancer cells showed different responses to different doses of amygdalin. This may suggest many in vitro models of the activity of this compound. The aim of the study was to evaluate the effect of amygdalin on MCF-7, MDA-MB-231, and T-47D breast cancer cells and on HFF-1 normal dermal fibroblasts (control cell culture) in vitro. Cell proliferation, viability, and the changes in mRNA transcript levels of basic proteins (BAX, caspase 3 and BCL-2) involved in apoptosis were analyzed.

Materials and Methods

MCF-7, MDA-MB-231, T-47D, and HFF-1 cell lines were purchased from the ATCC. Amygdalin derived from apricot kernels was purchased from Sigma-Aldrich. CVDE, WST-1, and LDH assays were used to evaluate the effects of amygdalin on cell proliferation and viability. Molecular evaluation of gene transcription levels was performed using the RT-qPCR technique.

Results

Amygdalin causes a dose-dependent decrease in proliferation and metabolic activity of MCF-7, MDA-MB-231, and T-47D cells in the in vitro cultures. In all cell cultures amygdalin affects the mRNA levels of pro-apoptotic BAX and caspase 3 proteins and anti-apoptotic BCL-2 protein.

Conclusions

Amygdalin anti-cancer activity may be selective in relation to different cell types. It seems that examined breast cancer cells are more sensitive to amygdalin than normal cells.

Language: English
Page range: 132 - 142
Submitted on: Mar 30, 2021
Accepted on: Jan 12, 2022
Published on: Apr 25, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Aleksandra Zielińska, Justyna Płonka-Czerw, Agnieszka Nowak, Dariusz Kuśmierz, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.